• One drop works to significantly reduce redness, with results lasting up to 12 hours1
• Lasts up to 50% longer than Lumify1-2,*
• Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months

Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration (FDA) has approved BRYTLY® Redness Reliever Eye Drops. With one drop, BRYTLY works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking eyes.1 Additionally, BRYTLY lasts up to 50% longer than Lumify.1-2,* The approval brings a differentiated new option to the over the counter (OTC) redness-relief category and expands Alcon’s portfolio of trusted consumer eye care products.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.